Paper 22 - A MULTI-CENTER PHASE II STUDY OF THE ANTI-GD2 HUMANIZED MONOCLONAL ANTIBODY NAXITAMAB IN COMBINATION WITH GM-CSF IN RECURRENT OSTEOSARCOMA.

Author(s)

• 

  Filemon S. Dela Cruz, MD (he/him/his)

  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

  Slides

Co-Author(s)

• AM

  Audrey Mauguen, PhD

  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• LP

  Liela Piracha, BS

  Clinical Research Coordinator
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• CW

  Charlie White, MS

  Research Biostatistician
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• NM

  Nicole Manino, n/a

  Clinical Research Supervisor
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• CP

  Catherine Poulcallec, n/a

  Clinical Research Nurse
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• HM

  Hassan Musleh, MD

  Clinical Research Manager
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• FN

  Fariba Navid, MD

  Professor of Clinical Pediatrics
  Children's Hospital Los Angeles
  Los Angeles, California, United States
• JG

  Jonathan B. Gill, MD

  Professor
  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• DH

  Douglas J. Harrison, MD

  Professor of Pediatrics
  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• MB

  Melissa A. Burns, MD

  Assistant Professor of Pediatrics
  Harvard Medical School/Dana-Farber Cancer Institute
  Boston, Massachusetts, United States
• ES

  Emily K. Slotkin, MD

  Assistant Attending Pediatrician
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• JG

  Julia Glade Bender, MD

  Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• MO

  Michael V. Ortiz, MD

  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• LW

  Leonard H. Wexler, MD

  Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• CP

  Christine A. Pratilas, MD

  Associate Professor of Oncology & Pediatrics
  Johns Hopkins University School of Medicine
  Baltimore, Maryland, United States
• IC

  Irene Y. Cheung, ScD

  Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• SM

  Shakeel Modak, MD

  Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• FI

  Fiorella Iglesias Cardenas, MD

  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• EB

  Ellen M. Basu, MD PhD

  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• 

  Alexander J. Chou, MD

  Professor of Clinical Pediatrics
  Weill Cornell Medical College
  New York, New York, United States
• SR

  Stephen S. Roberts, MD

  Division Head & Chair of Pediatric Oncology
  Oregon Health Sciences University
  Portland, Oregon, United States
• NC

  Nai-Kong V. Cheung, MD PhD

  Enid A. Haupt Chair in Pediatric Oncology
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• PM

  Paul A. Meyers, MD

  Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States